RPG Life Sciences, an India-based pharma products manufacturer, reported profit before tax (PBT) of INR 8.95 crores for the fourth quarter of the year that ended 31 March 2021 compared to INR 3.14 crores for the same period of the previous fiscal year.

The pharma company’s Q4 FY21 revenue was INR 92.76 crores compared to INR 88.67 crores for Q4 FY20.

For the full year, RPG Life Sciences posted INR 53.58 crores in profit before tax compared to INR 36.45 crores for the fiscal year 2020.

On the other hand, FY21 revenue of the Indian pharma company increased to INR 389.14 crores from FY20 revenue of INR 375.57 crores.

Yugal Sikri – Managing Director of RPG Life Sciences said: “In FY21, the overall performance of the Company continued to be strong, despite impact of extended Covid‐19 pandemic. On full year basis, revenues and PBT grew by 4% and 47% respectively. EBITDA margin retained its upward trajectory growing from 15.9% to 18.2%. We continue to be focused on executing our turnaround strategy.

“It comprises of five initiatives viz. Product portfolio rejuvenation by building chronic and specialty portfolio with new launches; Building our strategic brand assets through life cycle management by introducing line extensions; Deepening our customer coverage in targeted therapies by expanding our field force and deploying digital; Augmenting sales force effectiveness by competencies building initiatives and Improving profitability by opex control, efficient manufacturing operations and sales hygiene.”

A part of RPG Enterprises, the company operates in India and international markets in the branded formulations, synthetic APIs, and global generics space.

  India, RPG Enterprises, RPG Life Sciences, Yugal Sikri